BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
BD (BDX) reported strong Q4 and FY2024 results with Q4 revenue reaching $5.4 billion, up 6.9% as reported. Fourth quarter GAAP and adjusted diluted EPS from continuing operations grew 173.6% and 11.4% to $1.45 and $3.81 respectively. Full-year revenue reached $20.2 billion, with organic growth of 5.0%. FY2024 cash from continuing operations increased 28.5% to $3.8 billion, while Free Cash Flow grew 47.4% to $3.1 billion. The company provided FY2025 guidance projecting organic growth of 4.0% to 4.5% and adjusted diluted EPS growth of approximately 10% at midpoint.
BD (BDX) ha riportato risultati solidi per il quarto trimestre e l'intero anno fiscale 2024, con un fatturato nel quarto trimestre che ha raggiunto 5,4 miliardi di dollari, in aumento del 6,9% rispetto all'anno precedente. L'utile per azione diluito GAAP e l'utile per azione diluito rettificato delle operazioni continuative sono cresciuti rispettivamente del 173,6% e dell'11,4%, raggiungendo $1,45 e $3,81. Il fatturato dell'anno fiscale 2024 ha raggiunto 20,2 miliardi di dollari, con una crescita organica del 5,0%. Il flusso di cassa dalle operazioni continuative per l'anno fiscale 2024 è aumentato del 28,5%, arrivando a 3,8 miliardi di dollari, mentre il flusso di cassa libero è cresciuto del 47,4%, raggiungendo 3,1 miliardi di dollari. La società ha fornito indicazioni per l'anno fiscale 2025, prevedendo una crescita organica del 4,0% al 4,5% e una crescita dell'utile per azione diluito rettificato di circa il 10% al punto intermedio.
BD (BDX) informó resultados sólidos para el cuarto trimestre y el año fiscal 2024, con ingresos del cuarto trimestre que alcanzaron 5.4 mil millones de dólares, un aumento del 6.9% en comparación con el año anterior. Las ganancias por acción diluida GAAP y las ganancias por acción diluida ajustada de las operaciones continuas crecieron un 173.6% y un 11.4% hasta $1.45 y $3.81, respectivamente. Los ingresos del año fiscal 2024 alcanzaron 20.2 mil millones de dólares, con un crecimiento orgánico del 5.0%. El flujo de efectivo de las operaciones continuas del año fiscal 2024 aumentó un 28.5% a 3.8 mil millones de dólares, mientras que el flujo de efectivo libre creció un 47.4% a 3.1 mil millones de dólares. La empresa proporcionó orientaciones para el año fiscal 2025, proyectando un crecimiento orgánico del 4.0% al 4.5% y un crecimiento de las ganancias por acción diluida ajustada de aproximadamente el 10% en el punto medio.
BD (BDX)는 2024 회계연도 4분기 및 전체 연도 실적이 강력하다고 보고했습니다. 4분기 수익은 54억 달러에 이르렀으며, 이는 6.9% 증가한 수치입니다. GAAP 및 조정 후 희석 주당 순이익(EPS)은 지속적 운영에서 각각 173.6% 및 11.4% 증가하여 $1.45 및 $3.81에 도달했습니다. 2024 회계연도 전체 수익은 202억 달러에 이르렀으며, 유기적 성장은 5.0%였습니다. 2024 회계연도 지속적 운영으로부터의 현금흐름은 28.5% 증가하여 38억 달러에 도달했고, 자유 현금 흐름은 47.4% 증가하여 31억 달러에 이르렀습니다. 회사는 2025 회계연도에 대한 가이던스를 제공하며 유기적 성장은 4.0%에서 4.5% 사이로, 조정된 희석 EPS는 중간 지점에서 약 10% 성장할 것으로 예상하고 있습니다.
BD (BDX) a rapporté de solides résultats pour le quatrième trimestre et l'année fiscale 2024, avec un chiffre d'affaires au quatrième trimestre atteignant 5,4 milliards de dollars, en hausse de 6,9 % par rapport à l'année précédente. Le bénéfice par action dilué selon les PCGR et le bénéfice par action dilué ajusté des opérations continues ont augmenté respectivement de 173,6 % et de 11,4 %, pour atteindre 1,45 $ et 3,81 $. Le chiffre d'affaires de l'année fiscale 2024 a atteint 20,2 milliards de dollars, avec une croissance organique de 5,0 %. Le flux de trésorerie provenant des opérations continues pour l'année fiscale 2024 a augmenté de 28,5 %, atteignant 3,8 milliards de dollars, tandis que le flux de trésorerie disponible a augmenté de 47,4 %, atteignant 3,1 milliards de dollars. L'entreprise a fourni des prévisions pour l'année fiscale 2025, projetant une croissance organique de 4,0 % à 4,5 % et une croissance du bénéfice par action dilué ajusté d'environ 10 % à la valeur médiane.
BD (BDX) hat starke Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 gemeldet, wobei die Einnahmen im vierten Quartal 5,4 Milliarden US-Dollar erreichten, was einem Anstieg von 6,9% entspricht. Der GAAP- und der bereinigte verwässerte Gewinn pro Aktie (EPS) aus fortgeführten Aktivitäten wuchsen um 173,6% bzw. 11,4% auf $1,45 und $3,81. Der Gesamtumsatz des Geschäftsjahres 2024 betrug 20,2 Milliarden US-Dollar und wies ein organisches Wachstum von 5,0% auf. Der Cashflow aus fortgeführten Aktivitäten im Geschäftsjahr 2024 stieg um 28,5% auf 3,8 Milliarden US-Dollar, während der freie Cashflow um 47,4% auf 3,1 Milliarden US-Dollar zunahm. Das Unternehmen gab eine Prognose für das Geschäftsjahr 2025 ab, die ein organisches Wachstum von 4,0% bis 4,5% und ein Wachstum des bereinigten verwässerten EPS von etwa 10% im Mittelwert prognostiziert.
- Q4 revenue increased 6.9% to $5.4 billion
- Q4 adjusted EPS grew 11.4% to $3.81
- FY24 organic revenue growth of 5.0%
- Free Cash Flow increased 47.4% to $3.1 billion
- FY24 cash from operations up 28.5% to $3.8 billion
- Projected FY25 adjusted EPS growth of ~10%
- None.
Insights
BD's Q4 and FY24 results demonstrate robust financial performance with significant improvements across key metrics. Q4 revenue reached
The FY25 guidance suggests continued momentum, projecting organic growth of
The medical technology sector transformation through AI, automation and biologics presents significant growth opportunities for BD. Their strategic focus on these emerging technologies, coupled with the Critical Care acquisition, strengthens their market position. The
Strong Growth and Margin Execution Drives Performance in Quarter
- Q4 revenue of
increased$5.4 billion 6.9% as reported,7.4% currency-neutral and6.2% organic - Q4 GAAP and adjusted diluted EPS from continuing operations of
and$1.45 grew$3.81 173.6% and11.4% , respectively - FY24 revenue of
increased$20.2 billion 4.2% as reported and currency neutral,4.6% adjusted currency-neutral, and5.0% organic - FY24 GAAP and adjusted diluted EPS from continuing operations of
and$5.93 grew$13.14 16.3% and7.6% , respectively - FY24 cash from continuing operations grew
28.5% to and Free Cash Flow grew$3.8 billion 47.4% to , increasing$3.1 billion and$0.9 billion since the prior year, respectively$1.0 billion - Company issues FY25 revenue guidance including GAAP growth of
8.9% to9.4% , adjusted currency-neutral growth of8.8% to9.3% and organic growth of4.0% to4.5% - Company issues FY25 adjusted diluted EPS guidance of
to$14.25 1, which reflects growth of about$14.60 10% at the midpoint
"In FY24, our team advanced our strategy, continuing to shift our portfolio into higher-growth areas through new innovations and the acquisition of Edwards Lifesciences' Critical Care product group, while leveraging our BD Excellence system to exceed our margin expansion, earnings and cash flow goals," said Tom Polen, chairman, CEO and president of BD. "Our growth strategy remains focused on delivering solutions for our customers that leverage significant shifts in technology, like biologics, AI and automation, that are revolutionizing patient care. Combined with accelerated operational performance through BD Excellence and strong capital deployment, we are poised to deliver continued value creation for our shareholders."
1 BD does not attempt to provide reconciliations of forward-looking adjusted diluted EPS guidance to the comparable GAAP measure. See the discussion below under "Assumptions and Outlook for Full Year Fiscal 2025." |
Recent Business and Corporate Sustainability Highlights
- The company completed the acquisition of Critical Care from Edwards Lifesciences, expanding BD's portfolio of smart connected care solutions with monitoring technologies, including advanced AI-enabled clinical decision tools. The combination of leading monitoring and infusion platforms enables future innovation opportunities for closed-loop monitoring and treatment by integrating combined company data sets and interoperability capabilities.
- BD celebrated 75 years of
U.S. manufacturing excellence inNebraska where itsColumbus site produces billions of vital medical supplies each year and where, for the first nine months of 2024, it boosted domestic syringe production to help improve supply continuity to health care providers and their patients. - BD Life Sciences:
- The Integrated Diagnostic Solutions business unit announced Health Canada approval of the BD Onclarity™ HPV Assay for human papillomavirus (HPV) testing for the use with self-collected vaginal specimens at home.
- The Biosciences business unit announced a new robotics solution to automate and standardize single-cell research with the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits for use with the Hamilton Robotics Liquid-Handler, helping accelerate lab work leading to genomic sequencing.
- BD Medical:
- The Medication Delivery Solutions business unit announced:
- The launch of the new BD® Intraosseous Vascular Access System, enabling access in seconds for rapid delivery of fluids or medication in critical emergency situations.
- New data that shows BD MaxPlus™ and BD MaxZero™ Needle-free Connectors demonstrate better clinical outcomes with lower rate of central line bloodstream infections, fewer occlusions and cost savings.
- The Medication Management Solutions business unit announced new data that reveals the use of advanced artificial intelligence in BD HealthSight™ Diversion Management software is highly effective in detecting indicators of controlled substance diversion in the operating room.
- The Pharmaceutical Systems business unit announced:
- The latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform, a significant milestone that enables unprecedented large-scale production of advanced BD glass syringes to serve the growing market for biologic therapies.
- The commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe with features that enhance the injection experience for the next generation of biologics, expanding the usability of the BD Neopak™ platform.
- These expansions add to BD's leadership in offering a broad range of injection solutions to enable delivery of treatments such as GLP-1s, antibodies and other next generation treatments for chronic disease.
- The Medication Delivery Solutions business unit announced:
- Named a Best Place to Work for Disability Inclusion for the sixth consecutive year following its top score on the Disability Equality Index.
- Named among the 100 Best Corporate Citizens of 2024 by 3BL, ranking second in the health care equipment and services industry.
Fourth Quarter Fiscal 2024 Operating Results
Three Months Ended | Change | Foreign Currency | Organic Revenue | |||||||
(Millions of dollars, except per share amounts) | 2024 | 2023 | ||||||||
Revenues | $ 5,437 | $ 5,087 | 6.9 % | 7.4 % | 6.2 % | |||||
Reported Diluted Earnings per Share from Continuing Operations | $ 1.45 | $ 0.53 | 173.6 % | 198.1 % | ||||||
Adjusted Diluted Earnings per Share from Continuing Operations1 | $ 3.81 | $ 3.42 | 11.4 % | 15.2 % |
1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables. |
2Organic Revenue growth denotes foreign currency neutral revenues further adjusted for the impact to revenues from acquisitions and divestitures during the first 12 months post-acquisition/divestiture. |
Geographic Results
Revenues (Millions of dollars) | Three Months Ended | Reported Change | Foreign Currency | |||||
2024 | 2023 | |||||||
$ 3,117 | $ 2,879 | 8.3 % | 8.3 % | |||||
International | $ 2,320 | $ 2,209 | 5.1 % | 6.3 % | ||||
Total Revenues | $ 5,437 | $ 5,087 | 6.9 % | 7.4 % |
1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables. |
Segment Results
Revenues (Millions of dollars) | Three Months Ended | Reported Change | Foreign Currency | Organic Revenue Change1,2 | ||||||
2024 | 2023 | |||||||||
BD Medical | $ 2,837 | $ 2,554 | 11.1 % | 11.5 % | 8.6 % | |||||
BD Life Sciences | $ 1,340 | $ 1,330 | 0.7 % | 1.4 % | 1.4 % | |||||
BD Interventional | $ 1,260 | $ 1,203 | 4.7 % | 5.4 % | 6.6 % | |||||
Total Revenues | $ 5,437 | $ 5,087 | 6.9 % | 7.4 % | 6.2 % |
1Represents a non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in the attached financial tables. |
2Organic Revenue growth denotes foreign currency neutral revenues further adjusted for the impact to revenues from acquisitions and divestitures during the first 12 months post-acquisition/divestiture. |
The BD Medical segment includes the Medication Delivery Solutions (MDS), Medication Management Solutions (MMS) and Pharmaceutical Systems (PS) business units, and the Advanced Patient Monitoring (APM) business unit, which was formed upon the closing of the acquisition of Critical Care from Edwards Lifesciences. The segment's performance includes the revenues of APM from September 3, 2024 to September 30, 2024. BD Medical organic revenue growth was led by MMS.
- MDS performance reflects strong volume growth across the portfolio with increased share in Vascular Access Management and hypodermic products.
- MMS performance reflects high double-digit growth in Infusion driven by BD Alaris™ and higher utilization of infusion sets that was partially offset by the prior-year comparison in Dispensing Solutions.
- PS performance reflects double-digit growth in Biologics, including GLP-1s, that was partially offset by expected transitory market dynamics including customer inventory de-stocking in anti-coagulants and vaccines.
The BD Life Sciences segment includes the Integrated Diagnostic Solutions (IDS) and Biosciences (BDB) business units. BD Life Sciences revenue growth was driven by IDS.
- IDS performance reflects strong growth in Specimen Management driven by broad volume strength, and double-digit growth in BD MAX™ IVD and BD COR™ that was partially offset by the prior-year comparison in Microbiology.
- BDB performance reflects transitory market dynamics that resulted in lower market demand for research instruments partially offset by strong growth in clinical solutions that was driven by the FACSLyric™ Clinical Cell Analyzer and cancer reagents.
The BD Interventional segment includes the Surgery, Peripheral Intervention (PI), and Urology & Critical Care (UCC) business units. BD Interventional organic revenue growth was driven by performance across the segment.
- Surgery performance reflects double-digit growth in Infection Prevention and Phasix™ hernia resorbable scaffold that was partially offset by a tough prior-year comparison in Advanced Repair & Reconstruction. The unit's performance also reflects the impact from the divestiture of the Surgical Instrumentation platform.
- PI performance reflects double-digit growth in the Peripheral Vascular Disease portfolio and strong growth in End Stage Kidney Disease that was partially offset by a decline in
U.S. Oncology due to prior year distributor stocking. - UCC performance reflects strong double-digit growth in the PureWick™ franchise with continued adoption of both the Male and Female portfolios.
Assumptions and Outlook for Full Year Fiscal 2025
The company provided the following guidance with respect to fiscal 2025. GAAP revenue growth of
Fiscal 2025 Guidance as of | |
GAAP Revenues | |
GAAP Revenue Growth | |
Adjusted Revenue Growth (FXN) | |
Organic Revenue Growth (FXN) | |
Adjusted Diluted EPS | |
Adjusted Diluted EPS Growth | ~ |
BD's outlook for fiscal 2025 reflects numerous assumptions about many factors that could affect its business, based on the information management has reviewed as of this date. Management will discuss its outlook and several of its assumptions on its fourth fiscal quarter earnings call.
The company's expected adjusted diluted EPS for fiscal 2025 excludes potential charges or gains that may be recorded during the fiscal year, such as, among other things, the non-cash amortization of intangible assets, acquisition-related charges, spin-related costs, and certain tax matters. BD does not attempt to provide reconciliations of forward-looking adjusted diluted non-GAAP EPS guidance to the comparable GAAP measure because the impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of BD's financial performance. We also present our estimated adjusted revenue growth and organic revenue growth for our 2025 fiscal year after adjusting for the illustrative impact of foreign currency translation. BD believes that this adjustment allows investors to better evaluate BD's anticipated underlying earnings performance for our 2025 fiscal year in relation to our underlying 2024 fiscal year performance.
Conference Call and Presentation Materials
BD will host an audio webcast today for the public, investors, analysts, and news media to discuss its fourth quarter results. The audio webcast will be broadcast live on BD's website, www.bd.com/investors at 8 a.m. (ET) Thursday, November 7, 2024. Accompanying slides will be available on BD's website, www.bd.com/investors at approximately 6:30 a.m. (ET). The conference call will be available for replay on BD's website, www.bd.com/investors. Alternatively, you can dial into the replay at 800-839-1337 (domestic) and 402-220-0489 (international) through the close of business on Thursday, November 14, 2024. A confirmation number is not needed to access the replay.
Non-GAAP Financial Measures/Financial Tables
This news release contains certain non-GAAP financial measures. These include adjusted revenues, revenue growth rates on a currency-neutral, adjusted, and organic basis, adjusted diluted earnings per share from continuing operations, and free cash flow. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in
We present adjusted revenues for the full fiscal year 2024 after eliminating the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, which substantially relate to years prior to the current fiscal year, because we believe these items affect the comparability of the periods presented to prior periods.
We also present adjusted diluted earnings per share from continuing operations for the fourth quarter and full fiscal year 2024, and the corresponding prior periods, after eliminating items we believe are not part of our ordinary operations and affect the comparability of the periods presented. Adjusted diluted earnings per share from continuing operations includes adjustments for the impact of purchase accounting adjustments, integration and restructuring costs, transaction and financing costs, spin-off related costs, certain regulatory costs, certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. In particular, current and prior-year adjusted diluted earnings per share from continuing operations results exclude European regulatory initiative-related costs, which represent costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation (collectively, the "New EU Medical Devices Regulations"), which represent a significant, unusual change to the existing regulatory framework. We consider the excluded European regulatory initiative-related costs to be duplicative of previously incurred costs and/or one-off costs related to establishing initial compliance with such regulatory regimes, and in each case are limited to a specific period of time. These expenses relate to establishing initial compliance with the New EU Medical Devices Regulations and include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. These costs were recorded in Cost of products sold and Research and development expense.
We also present revenue growth rates for the fourth quarter and full fiscal year 2024 over the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We also show the growth in adjusted diluted earnings per share from continuing operations compared to the prior year periods after eliminating the impact of foreign currency translation to further enable investors to evaluate BD's underlying earnings performance compared to the prior periods. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior periods.
We also present free cash flow for the full fiscal year 2024 over the corresponding prior period, which is net cash provided by continuing operating activities less capital expenditures, to provide a view of the Company's ability to generate cash for use in acquisitions and other investing and financing activities. Free cash flow is not a measure of cash available for discretionary expenditures given that we have certain non-discretionary obligations such as debt service that are not deducted from the measure. We believe the presentation of results of free cash flow in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to the prior period.
Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and on X (formerly known as Twitter) @BDandCo.
***
This press release and accompanying audio webcast on November 7, 2024 contain certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues, margins, earnings per share, leverage targets and capital deployment. All such statements are based upon current expectations and assumptions of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to such forward-looking statements, a number of factors could cause actual results to vary materially. These factors include, but are not limited to, risks relating to macroeconomic conditions and their impact on our operations and healthcare spending generally, including any impact of disruptions in the global transportation networks or other aspects of our supply chain on our ability to source raw materials, components and energy sources needed to produce our products, labor constraints or disputes, inflationary pressures, currency rate fluctuations, and increased interest rates and borrowing costs; conditions in international markets, including geopolitical developments such as the evolving situations in
Contacts:
Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927
Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited; Amounts in millions, except share and per share data)
| ||||||||||||||||||||
Three Months Ended September 30, | ||||||||||||||||||||
2024 | 2023 | % Change | ||||||||||||||||||
REVENUES | $ | 5,437 | $ | 5,087 | 6.9 | |||||||||||||||
Cost of products sold | 2,922 | 3,386 | (13.7) | |||||||||||||||||
Selling and administrative expense | 1,256 | 1,137 | 10.4 | |||||||||||||||||
Research and development expense | 302 | 281 | 7.7 | |||||||||||||||||
Integration, restructuring and transaction expense | 170 | 138 | 23.2 | |||||||||||||||||
Other operating expense (income), net | 137 | (203) | 167.3 | |||||||||||||||||
TOTAL OPERATING COSTS AND EXPENSES | 4,787 | 4,738 | 1.0 | |||||||||||||||||
OPERATING INCOME | 650 | 349 | 86.4 | |||||||||||||||||
Interest expense | (155) | (114) | 36.3 | |||||||||||||||||
Interest income | 56 | 9 | 493.7 | |||||||||||||||||
Other expense, net | (9) | (63) | 85.1 | |||||||||||||||||
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 542 | 181 | 198.8 | |||||||||||||||||
Income tax provision | 121 | 27 | 342.5 | |||||||||||||||||
NET INCOME FROM CONTINUING OPERATIONS | 421 | 154 | 173.2 | |||||||||||||||||
Loss from Discontinued Operations, Net of Tax | — | (46) | 100.0 | |||||||||||||||||
NET INCOME APPLICABLE TO COMMON SHAREHOLDERS | $ | 421 | $ | 108 | 290.1 | |||||||||||||||
BASIC EARNINGS PER SHARE | ||||||||||||||||||||
Income from Continuing Operations | 1.45 | 0.53 | 173.6 | |||||||||||||||||
Loss from Discontinued Operations | — | (0.16) | 100.0 | |||||||||||||||||
Basic Earnings per Share | $ | 1.45 | $ | 0.37 | 291.9 | |||||||||||||||
DILUTED EARNINGS PER SHARE | ||||||||||||||||||||
Income from Continuing Operations | 1.45 | 0.53 | 173.6 | |||||||||||||||||
Loss from Discontinued Operations | — | (0.16) | 100.0 | |||||||||||||||||
Diluted Earnings per Share | $ | 1.45 | $ | 0.37 | 291.9 | |||||||||||||||
AVERAGE SHARES OUTSTANDING (in thousands) | ||||||||||||||||||||
Basic | 289,607 | 290,590 | ||||||||||||||||||
Diluted | 290,602 | 292,701 |
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited; Amounts in millions, except share and per share data)
| ||||||||||||||||||||
Twelve Months Ended September 30, | ||||||||||||||||||||
2024 | 2023 | % Change | ||||||||||||||||||
REVENUES | $ | 20,178 | $ | 19,372 | 4.2 | |||||||||||||||
Cost of products sold | 11,025 | 11,202 | (1.6) | |||||||||||||||||
Selling and administrative expense | 4,857 | 4,719 | 2.9 | |||||||||||||||||
Research and development expense | 1,190 | 1,237 | (3.8) | |||||||||||||||||
Integration, restructuring and transaction expense | 458 | 313 | 46.2 | |||||||||||||||||
Other operating expense (income), net | 222 | (210) | 206.0 | |||||||||||||||||
TOTAL OPERATING COSTS AND EXPENSES | 17,752 | 17,261 | 2.8 | |||||||||||||||||
OPERATING INCOME | 2,425 | 2,111 | 14.9 | |||||||||||||||||
Interest expense | (528) | (452) | 16.7 | |||||||||||||||||
Interest income | 163 | 49 | 233.5 | |||||||||||||||||
Other expense, net | (28) | (46) | 38.3 | |||||||||||||||||
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 2,033 | 1,662 | 22.3 | |||||||||||||||||
Income tax provision | 307 | 132 | 133.0 | |||||||||||||||||
NET INCOME FROM CONTINUING OPERATIONS | 1,726 | 1,530 | 12.8 | |||||||||||||||||
Loss from Discontinued Operations, Net of Tax | — | (46) | 100.0 | |||||||||||||||||
NET INCOME | 1,726 | 1,484 | 16.3 | |||||||||||||||||
Preferred stock dividends | — | (60) | (100.0) | |||||||||||||||||
NET INCOME APPLICABLE TO COMMON SHAREHOLDERS | $ | 1,726 | $ | 1,424 | 21.2 | |||||||||||||||
BASIC EARNINGS PER SHARE | ||||||||||||||||||||
Income from Continuing Operations | 5.96 | 5.14 | 16.0 | |||||||||||||||||
Loss from Discontinued Operations | — | (0.16) | 100.0 | |||||||||||||||||
Basic Earnings per Share | $ | 5.96 | $ | 4.97 | 19.9 | |||||||||||||||
DILUTED EARNINGS PER SHARE | ||||||||||||||||||||
Income from Continuing Operations | 5.93 | 5.10 | 16.3 | |||||||||||||||||
Loss from Discontinued Operations | — | (0.16) | 100.0 | |||||||||||||||||
Diluted Earnings per Share | $ | 5.93 | $ | 4.94 | 20.0 | |||||||||||||||
AVERAGE SHARES OUTSTANDING (in thousands) | ||||||||||||||||||||
Basic | 289,763 | 286,282 | ||||||||||||||||||
Diluted | 291,009 | 288,392 |
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited; Amounts in millions)
| ||||||||||||||
September 30, 2024 | September 30, 2023 | |||||||||||||
ASSETS | ||||||||||||||
Cash and equivalents | $ | 1,717 | $ | 1,416 | ||||||||||
Restricted cash | 139 | 65 | ||||||||||||
Short-term investments | 445 | 8 | ||||||||||||
Trade receivables, net | 3,033 | 2,534 | ||||||||||||
Inventories | 3,843 | 3,273 | ||||||||||||
Prepaid expenses and other | 1,292 | 1,380 | ||||||||||||
TOTAL CURRENT ASSETS | 10,468 | 8,676 | ||||||||||||
Property, plant and equipment, net | 6,821 | 6,557 | ||||||||||||
Goodwill and other intangibles, net | 37,383 | 35,469 | ||||||||||||
Other assets | 2,615 | 2,078 | ||||||||||||
TOTAL ASSETS | $ | 57,286 | $ | 52,780 | ||||||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||
Current debt obligations | $ | 2,170 | $ | 1,141 | ||||||||||
Other current liabilities | 6,777 | 5,500 | ||||||||||||
Long-term debt | 17,940 | 14,738 | ||||||||||||
Long-term employee benefit obligations | 942 | 1,023 | ||||||||||||
Deferred income taxes and other liabilities | 3,546 | 4,582 | ||||||||||||
Shareholders' equity | 25,911 | 25,796 | ||||||||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 57,286 | $ | 52,780 |
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited; Amounts in millions)
| ||||||||||||||
Twelve Months Ended September 30, | ||||||||||||||
2024 | 2023 | |||||||||||||
OPERATING ACTIVITIES | ||||||||||||||
Net income | $ | 1,726 | $ | 1,484 | ||||||||||
Less: Loss from discontinued operations, net of tax | — | (46) | ||||||||||||
Income from continuing operations, net of tax | 1,726 | 1,530 | ||||||||||||
Depreciation and amortization | 2,286 | 2,288 | ||||||||||||
Change in operating assets and liabilities and other, net | (168) | (828) | ||||||||||||
NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES | 3,844 | 2,990 | ||||||||||||
INVESTING ACTIVITIES | ||||||||||||||
Capital expenditures | (725) | (874) | ||||||||||||
Acquisitions, net of cash acquired | (3,924) | — | ||||||||||||
Proceeds from divestiture, net | — | 540 | ||||||||||||
Purchases of investments, net | (421) | — | ||||||||||||
Other, net | (444) | (382) | ||||||||||||
NET CASH USED FOR CONTINUING INVESTING ACTIVITIES | (5,514) | (716) | ||||||||||||
FINANCING ACTIVITIES | ||||||||||||||
Change in short-term debt | 400 | (230) | ||||||||||||
Proceeds from long-term debt | 4,517 | 1,662 | ||||||||||||
Payments of debt | (1,142) | (2,155) | ||||||||||||
Repurchases of common stock | (500) | — | ||||||||||||
Dividends paid | (1,100) | (1,114) | ||||||||||||
Other, net | (89) | (120) | ||||||||||||
NET CASH PROVIDED BY (USED FOR) CONTINUING FINANCING ACTIVITIES | 2,087 | (1,956) | ||||||||||||
Net cash used for operating activities of discontinued operations | (46) | (1) | ||||||||||||
Effect of exchange rate changes on cash and equivalents and restricted cash | 4 | 5 | ||||||||||||
NET INCREASE IN CASH AND EQUIVALENTS AND RESTRICTED CASH | 375 | 322 | ||||||||||||
OPENING CASH AND EQUIVALENTS AND RESTRICTED CASH | 1,481 | 1,159 | ||||||||||||
CLOSING CASH AND EQUIVALENTS AND RESTRICTED CASH | $ | 1,856 | $ | 1,481 |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS - Three Months Ended September 30, (Unaudited; Amounts in millions) | ||||||||||||||||||||
A | B | C=(A-B)/B | ||||||||||||||||||
2024 | 2023 | % Change | ||||||||||||||||||
BD MEDICAL | ||||||||||||||||||||
Medication Delivery Solutions | $ | 689 | $ | 656 | 5.0 | |||||||||||||||
Medication Management Solutions | 744 | 602 | 23.6 | |||||||||||||||||
Pharmaceutical Systems | 187 | 188 | (0.4) | |||||||||||||||||
Advanced Patient Monitoring | 47 | — | NM | |||||||||||||||||
TOTAL | $ | 1,667 | $ | 1,447 | 15.3 | |||||||||||||||
BD LIFE SCIENCES | ||||||||||||||||||||
Integrated Diagnostic Solutions | $ | 448 | $ | 447 | 0.2 | |||||||||||||||
Biosciences | 151 | 159 | (5.2) | |||||||||||||||||
TOTAL | $ | 598 | $ | 606 | (1.2) | |||||||||||||||
BD INTERVENTIONAL | ||||||||||||||||||||
Surgery | $ | 279 | $ | 279 | (0.1) | |||||||||||||||
Peripheral Intervention | 267 | 268 | (0.4) | |||||||||||||||||
Urology and Critical Care | 306 | 279 | 9.4 | |||||||||||||||||
TOTAL | $ | 851 | $ | 826 | 3.0 | |||||||||||||||
TOTAL | $ | 3,117 | $ | 2,879 | 8.3 |
"NM" denotes that the percentage change is not meaningful. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL Three Months Ended September 30, (continued) (Unaudited; Amounts in millions) | ||||||||||||||||||||||||||||||||
D=(A-B)/B | E=(A-B-C)/B | |||||||||||||||||||||||||||||||
A | B | C | % Change | |||||||||||||||||||||||||||||
2024 | 2023 | FX Impact | Reported | FXN | ||||||||||||||||||||||||||||
BD MEDICAL | ||||||||||||||||||||||||||||||||
Medication Delivery Solutions | $ | 458 | $ | 442 | $ | (8) | 3.6 | 5.5 | ||||||||||||||||||||||||
Medication Management Solutions | 195 | 194 | (1) | 0.3 | 0.6 | |||||||||||||||||||||||||||
Pharmaceutical Systems | 490 | 471 | (2) | 4.0 | 4.4 | |||||||||||||||||||||||||||
Advanced Patient Monitoring | 27 | — | — | NM | NM | |||||||||||||||||||||||||||
TOTAL | $ | 1,170 | $ | 1,107 | $ | (11) | 5.6 | 6.6 | ||||||||||||||||||||||||
BD LIFE SCIENCES | ||||||||||||||||||||||||||||||||
Integrated Diagnostic Solutions | $ | 495 | $ | 479 | $ | (7) | 3.4 | 4.9 | ||||||||||||||||||||||||
Biosciences | 247 | 246 | (1) | 0.4 | 1.0 | |||||||||||||||||||||||||||
TOTAL | $ | 742 | $ | 724 | $ | (9) | 2.4 | 3.6 | ||||||||||||||||||||||||
BD INTERVENTIONAL | ||||||||||||||||||||||||||||||||
Surgery | $ | 89 | $ | 87 | $ | (2) | 3.2 | 5.0 | ||||||||||||||||||||||||
Peripheral Intervention | 235 | 214 | (4) | 9.7 | 11.5 | |||||||||||||||||||||||||||
Urology and Critical Care | 84 | 76 | (2) | 11.0 | 13.8 | |||||||||||||||||||||||||||
TOTAL | $ | 409 | $ | 377 | $ | (8) | 8.5 | 10.5 | ||||||||||||||||||||||||
TOTAL INTERNATIONAL | $ | 2,320 | $ | 2,209 | $ | (27) | 5.1 | 6.3 |
"NM" denotes that the percentage change is not meaningful. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL Three Months Ended September 30, (continued) (Unaudited; Amounts in millions) | ||||||||||||||||||||||||||||||||
D=(A-B)/B | E=(A-B-C)/B | |||||||||||||||||||||||||||||||
A | B | C | % Change | |||||||||||||||||||||||||||||
2024 | 2023 | FX Impact | Reported | FXN | ||||||||||||||||||||||||||||
BD MEDICAL | ||||||||||||||||||||||||||||||||
Medication Delivery Solutions | $ | 1,147 | $ | 1,098 | $ | (8) | 4.4 | 5.2 | ||||||||||||||||||||||||
Medication Management Solutions | 939 | 796 | (1) | 17.9 | 18.0 | |||||||||||||||||||||||||||
Pharmaceutical Systems | 677 | 659 | (2) | 2.7 | 3.0 | |||||||||||||||||||||||||||
Advanced Patient Monitoring | 74 | — | — | NM | NM | |||||||||||||||||||||||||||
TOTAL | $ | 2,837 | $ | 2,554 | $ | (11) | 11.1 | 11.5 | ||||||||||||||||||||||||
BD LIFE SCIENCES | ||||||||||||||||||||||||||||||||
Integrated Diagnostic Solutions | $ | 943 | $ | 926 | $ | (7) | 1.8 | 2.6 | ||||||||||||||||||||||||
Biosciences | 397 | 405 | (1) | (1.8) | (1.4) | |||||||||||||||||||||||||||
TOTAL | $ | 1,340 | $ | 1,330 | $ | (9) | 0.7 | 1.4 | ||||||||||||||||||||||||
BD INTERVENTIONAL | ||||||||||||||||||||||||||||||||
Surgery | $ | 368 | $ | 366 | $ | (2) | 0.7 | 1.1 | ||||||||||||||||||||||||
Peripheral Intervention | 502 | 482 | (4) | 4.1 | 4.9 | |||||||||||||||||||||||||||
Urology and Critical Care | 390 | 355 | (2) | 9.7 | 10.3 | |||||||||||||||||||||||||||
TOTAL | $ | 1,260 | $ | 1,203 | $ | (8) | 4.7 | 5.4 | ||||||||||||||||||||||||
TOTAL REVENUES | $ | 5,437 | $ | 5,087 | $ | (27) | 6.9 | 7.4 |
"NM" denotes that the percentage change is not meaningful. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS - Twelve Months Ended September 30, (Unaudited; Amounts in millions) | ||||||||||||||||||||
A | B | C=(A-B)/B | ||||||||||||||||||
2024 | 2023 | % Change | ||||||||||||||||||
BD MEDICAL | ||||||||||||||||||||
Medication Delivery Solutions | $ | 2,661 | $ | 2,519 | 5.6 | |||||||||||||||
Medication Management Solutions | 2,627 | 2,303 | 14.1 | |||||||||||||||||
Pharmaceutical Systems | 629 | 666 | (5.5) | |||||||||||||||||
Advanced Patient Monitoring | 47 | — | NM | |||||||||||||||||
TOTAL | $ | 5,964 | $ | 5,488 | 8.7 | |||||||||||||||
BD LIFE SCIENCES | ||||||||||||||||||||
Integrated Diagnostic Solutions | $ | 1,733 | $ | 1,774 | (2.3) | |||||||||||||||
Biosciences | 577 | 603 | (4.4) | |||||||||||||||||
TOTAL | $ | 2,310 | $ | 2,377 | (2.8) | |||||||||||||||
BD INTERVENTIONAL | ||||||||||||||||||||
Surgery | $ | 1,130 | $ | 1,159 | (2.5) | |||||||||||||||
Peripheral Intervention | 1,029 | 1,016 | 1.3 | |||||||||||||||||
Urology and Critical Care | 1,236 | 1,073 | 15.2 | |||||||||||||||||
TOTAL | $ | 3,394 | $ | 3,247 | 4.5 | |||||||||||||||
Other(1) | $ | (6) | $ | — | NM | |||||||||||||||
TOTAL | $ | 11,663 | $ | 11,113 | 4.9 | |||||||||||||||
"NM" denotes that the percentage change is not meaningful. | |
(1) | Represents an accrual resulting from a legal matter and which substantially relates to years prior to the current fiscal year. This amount was not allocated to our reportable segments. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL Twelve Months Ended September 30, (continued) (Unaudited; Amounts in millions) | ||||||||||||||||||||||||||||||||
D=(A-B)/B | E=(A-B-C)/B | |||||||||||||||||||||||||||||||
A | B | C | % Change | |||||||||||||||||||||||||||||
2024 | 2023 | FX Impact | Reported | FXN | ||||||||||||||||||||||||||||
BD MEDICAL | ||||||||||||||||||||||||||||||||
Medication Delivery Solutions | $ | 1,768 | $ | 1,774 | $ | (4) | (0.3) | (0.1) | ||||||||||||||||||||||||
Medication Management Solutions | 670 | 677 | 5 | (1.0) | (1.7) | |||||||||||||||||||||||||||
Pharmaceutical Systems | 1,644 | 1,563 | 3 | 5.2 | 5.0 | |||||||||||||||||||||||||||
Advanced Patient Monitoring | 27 | — | — | NM | NM | |||||||||||||||||||||||||||
TOTAL | $ | 4,110 | $ | 4,014 | $ | 4 | 2.4 | 2.3 | ||||||||||||||||||||||||
BD LIFE SCIENCES | ||||||||||||||||||||||||||||||||
Integrated Diagnostic Solutions | $ | 1,946 | $ | 1,850 | $ | (2) | 5.2 | 5.3 | ||||||||||||||||||||||||
Biosciences | 935 | 906 | 1 | 3.3 | 3.2 | |||||||||||||||||||||||||||
TOTAL | $ | 2,881 | $ | 2,756 | $ | (1) | 4.6 | 4.6 | ||||||||||||||||||||||||
BD INTERVENTIONAL | ||||||||||||||||||||||||||||||||
Surgery | $ | 363 | $ | 338 | $ | (2) | 7.2 | 7.8 | ||||||||||||||||||||||||
Peripheral Intervention | 904 | 849 | (9) | 6.5 | 7.6 | |||||||||||||||||||||||||||
Urology and Critical Care | 319 | 301 | (7) | 5.7 | 7.9 | |||||||||||||||||||||||||||
TOTAL | $ | 1,586 | $ | 1,489 | $ | (18) | 6.5 | 7.7 | ||||||||||||||||||||||||
Other(1) | $ | (62) | $ | — | $ | — | NM | NM | ||||||||||||||||||||||||
TOTAL INTERNATIONAL | $ | 8,515 | $ | 8,258 | $ | (14) | 3.1 | 3.3 | ||||||||||||||||||||||||
"NM" denotes that the percentage change is not meaningful. | |
(1) | Represents the recognition of an accrual resulting from recent developments relating to the Italian government medical device pay back legislation and which substantially relates to years prior to the current fiscal year. This amount was not allocated to our reportable segments. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL Twelve Months Ended September 30, (continued) (Unaudited; Amounts in millions) | ||||||||||||||||||||||||||||||||
D=(A-B)/B | E=(A-B-C)/B | |||||||||||||||||||||||||||||||
A | B | C | % Change | |||||||||||||||||||||||||||||
2024 | 2023 | FX Impact | Reported | FXN | ||||||||||||||||||||||||||||
BD MEDICAL | ||||||||||||||||||||||||||||||||
Medication Delivery Solutions | $ | 4,429 | $ | 4,293 | $ | (4) | 3.2 | 3.3 | ||||||||||||||||||||||||
Medication Management Solutions | 3,297 | 2,980 | 5 | 10.7 | 10.5 | |||||||||||||||||||||||||||
Pharmaceutical Systems | 2,273 | 2,229 | 3 | 2.0 | 1.8 | |||||||||||||||||||||||||||
Advanced Patient Monitoring | 74 | — | — | NM | NM | |||||||||||||||||||||||||||
TOTAL | $ | 10,074 | $ | 9,502 | $ | 4 | 6.0 | 6.0 | ||||||||||||||||||||||||
BD LIFE SCIENCES | ||||||||||||||||||||||||||||||||
Integrated Diagnostic Solutions | $ | 3,679 | $ | 3,624 | $ | (2) | 1.5 | 1.6 | ||||||||||||||||||||||||
Biosciences | 1,512 | 1,509 | 1 | 0.2 | 0.2 | |||||||||||||||||||||||||||
TOTAL | $ | 5,191 | $ | 5,133 | $ | (1) | 1.1 | 1.1 | ||||||||||||||||||||||||
BD INTERVENTIONAL | ||||||||||||||||||||||||||||||||
Surgery | $ | 1,492 | $ | 1,497 | $ | (2) | (0.3) | (0.2) | ||||||||||||||||||||||||
Peripheral Intervention | 1,933 | 1,865 | (9) | 3.7 | 4.1 | |||||||||||||||||||||||||||
Urology and Critical Care | 1,554 | 1,374 | (7) | 13.1 | 13.6 | |||||||||||||||||||||||||||
TOTAL | $ | 4,980 | $ | 4,736 | $ | (18) | 5.1 | 5.5 | ||||||||||||||||||||||||
Other(1) | $ | (67) | $ | — | $ | — | NM | NM | ||||||||||||||||||||||||
TOTAL REVENUES | $ | 20,178 | $ | 19,372 | $ | (14) | 4.2 | 4.2 |
"NM" denotes that the percentage change is not meaningful. | |
(1) | Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to our reportable segments. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION RECONCILIATION OF REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE Three Months Ended September 30, (Unaudited; Amounts in millions) | ||||||||||||||||||||||||||||||||
D = (A-B)/B | E=(A-B-C)/B | |||||||||||||||||||||||||||||||
A | B | C | % Change | |||||||||||||||||||||||||||||
2024 | 2023 | FX Impact | Reported | FXN | ||||||||||||||||||||||||||||
TOTAL REVENUES | $ | 5,437 | $ | 5,087 | $ | (27) | 6.9 | 7.4 | ||||||||||||||||||||||||
Less: Inorganic revenue adjustment (1) | 74 | 14 | — | 444.6 | 444.6 | |||||||||||||||||||||||||||
Organic Revenue | $ | 5,363 | $ | 5,074 | $ | (27) | 5.7 | 6.2 | ||||||||||||||||||||||||
BD MEDICAL REVENUES | $ | 2,837 | $ | 2,554 | $ | (11) | 11.1 | 11.5 | ||||||||||||||||||||||||
Less: Inorganic revenue adjustment (1) | 74 | — | — | NM | NM | |||||||||||||||||||||||||||
BD Medical Organic Revenue | $ | 2,763 | $ | 2,554 | $ | (11) | 8.2 | 8.6 | ||||||||||||||||||||||||
BD INTERVENTIONAL REVENUES | $ | 1,260 | $ | 1,203 | $ | (8) | 4.7 | 5.4 | ||||||||||||||||||||||||
Less: Inorganic revenue adjustment (1) | — | 14 | — | (100.0) | (100.0) | |||||||||||||||||||||||||||
BD Interventional Organic Revenue | $ | 1,260 | $ | 1,190 | $ | (8) | 5.9 | 6.6 |
"NM" denotes that the percentage change is not meaningful. | |
(1) | Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Edwards Lifesciences' Critical Care Product Group, which was renamed as BD Advanced Patient Monitoring, in the Medical Segment. Divestitures include: the sale of the Surgical Instrumentation platform in the Interventional segment. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION RECONCILIATION OF REPORTED REVENUE CHANGE TO ADJUSTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE Twelve Months Ended September 30, (Unaudited; Amounts in millions) | ||||||||||||||||||||||||||||||||
D=(A-B)/B | E=(A-B-C)/B | |||||||||||||||||||||||||||||||
A | B | C | % Change | |||||||||||||||||||||||||||||
2024 | 2023 | FX Impact | Reported | FXN | ||||||||||||||||||||||||||||
TOTAL REVENUES | $ | 20,178 | $ | 19,372 | $ | (14) | 4.2 | 4.2 | ||||||||||||||||||||||||
Add: Reduction for government legislative and legal matters(1) | 67 | — | — | NM | NM | |||||||||||||||||||||||||||
Adjusted Total Revenues | $ | 20,245 | $ | 19,372 | $ | (14) | 4.5 | 4.6 | ||||||||||||||||||||||||
Less: Inorganic revenue adjustment (2) | $ | 74 | $ | 140 | $ | — | (46.9) | (46.9) | ||||||||||||||||||||||||
Organic Revenue | $ | 20,171 | $ | 19,232 | $ | (14) | 4.9 | 5.0 |
"NM" denotes that the percentage change is not meaningful. | |
(1) | Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. |
(2) | Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Edwards Lifesciences' Critical Care Product Group, which was renamed as BD Advanced Patient Monitoring, in the Medical Segment. Divestitures include: the sale of the Surgical Instrumentation platform in the Interventional segment. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION FROM NET CASH PROVIDED BY CONTINUING OPERATING ACTIVITIES TO FREE CASH FLOW Twelve Months Ended September 30, (Unaudited; Amounts in millions) | ||||||||||||||||||||||||||
A | B | C=A-B | D=C/B | |||||||||||||||||||||||
2024 | 2023 | Change | % Change | |||||||||||||||||||||||
Net Cash Provided by Continuing Operating Activities | $ | 3,844 | $ | 2,990 | $ | 854 | 28.5 | % | ||||||||||||||||||
Capital Expenditures | (725) | (874) | 149 | (17.0) | % | |||||||||||||||||||||
Free Cash Flow | $ | 3,119 | $ | 2,116 | $ | 1,002 | 47.4 | % |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS (Unaudited) | |||||||||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||||||||
2024 | 2023 | Change | FX Impact | FXN | Change % | FXN | |||||||||||||||||||||||||||||||||||
Reported Diluted Earnings per Share from Continuing Operations | $ | 1.45 | $ | 0.53 | $ | 0.92 | $ | (0.13) | $ | 1.05 | 173.6 % | 198.1 % | |||||||||||||||||||||||||||||
Purchase accounting adjustments ( | 1.47 | 1.24 | — | ||||||||||||||||||||||||||||||||||||||
Integration costs ( | 0.02 | 0.04 | — | ||||||||||||||||||||||||||||||||||||||
Restructuring costs ( | 0.43 | 0.41 | — | ||||||||||||||||||||||||||||||||||||||
Transaction Costs ( | 0.13 | — | — | ||||||||||||||||||||||||||||||||||||||
Financing Costs ( | (0.02) | — | — | ||||||||||||||||||||||||||||||||||||||
Separation-related items ( | 0.02 | 0.02 | — | ||||||||||||||||||||||||||||||||||||||
European regulatory initiative-related costs ( | 0.11 | 0.12 | — | ||||||||||||||||||||||||||||||||||||||
Product, litigation, and other items ( | 0.51 | 1.56 | — | ||||||||||||||||||||||||||||||||||||||
Tax impact of specified items and other tax related ( | (0.32) | (0.50) | — | ||||||||||||||||||||||||||||||||||||||
Adjusted Diluted Earnings per Share from Continuing Operations | $ | 3.81 | $ | 3.42 | $ | 0.39 | $ | (0.13) | $ | 0.52 | 11.4 % | 15.2 % |
(1) | Includes amortization and other adjustments related to the purchase accounting for acquisitions. |
(2) | Represents costs associated with integration and restructuring activities. |
(3) | Represents transaction costs and financing impacts associated with the acquisition of Edwards Lifesciences' Critical Care Product Group. The transaction costs are recorded in Integration, restructuring and transaction expense and the financing impacts are recorded in Interest income and Interest expense. |
(4) | Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business. |
(5) | Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. |
(6) | Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2024 reflects charges to Other operating expense (income), net related to legal matters, including a |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS (Unaudited) | |||||||||||||||||||||||||||||||||||||||||
Twelve Months Ended September 30, | |||||||||||||||||||||||||||||||||||||||||
2024 | 2023 | Change | FX Impact | FXN | Change % | FXN | |||||||||||||||||||||||||||||||||||
Reported Diluted Earnings per Share from Continuing Operations | $ | 5.93 | $ | 5.10 | $ | 0.83 | $ | (0.56) | $ | 1.39 | 16.3 | % | 27.3 | % | |||||||||||||||||||||||||||
Purchase accounting adjustments ( | 5.16 | 4.97 | — | ||||||||||||||||||||||||||||||||||||||
Integration costs ( | 0.08 | 0.23 | — | ||||||||||||||||||||||||||||||||||||||
Restructuring costs ( | 1.33 | 0.83 | 0.01 | ||||||||||||||||||||||||||||||||||||||
Transaction Costs ( | 0.17 | — | — | ||||||||||||||||||||||||||||||||||||||
Financing Costs ( | (0.03) | — | — | ||||||||||||||||||||||||||||||||||||||
Separation-related items ( | 0.05 | 0.05 | — | ||||||||||||||||||||||||||||||||||||||
European regulatory initiative-related costs ( | 0.36 | 0.48 | — | ||||||||||||||||||||||||||||||||||||||
Product, litigation, and other items ( | 1.09 | 1.92 | — | ||||||||||||||||||||||||||||||||||||||
Tax impact of specified items and other tax related ( | (1.00) | (1.38) | — | ||||||||||||||||||||||||||||||||||||||
Adjusted Diluted Earnings per Share from Continuing Operations | $ | 13.14 | $ | 12.21 | $ | 0.93 | $ | (0.55) | $ | 1.48 | 7.6 | % | 12.1 | % |
(1) | Includes amortization and other adjustments related to the purchase accounting for acquisitions. |
(2) | Represents costs associated with integration and restructuring activities. |
(3) | Represents transaction costs and financing impacts associated with the acquisition of Edwards Lifesciences' Critical Care Product Group. The transaction costs are recorded in Integration, restructuring and transaction expense and the financing impacts are recorded in Interest income and Interest expense. |
(4) | Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business. |
(5) | Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. |
(6) | Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2024 reflects the recognition of |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2025 OUTLOOK RECONCILIATION
| ||||||||||||||||||||
Full Year FY 2024 | Full Year FY 2025 Outlook | |||||||||||||||||||
($ in millions) | % Change | Revenues | ||||||||||||||||||
BDX Reported Revenues | $ | 20,178 | ||||||||||||||||||
Add: Revenue Adjustment Impact | 67 | |||||||||||||||||||
Adjusted Revenues | $ | 20,245 | ||||||||||||||||||
FY 2025 Reported Revenue Growth | + | |||||||||||||||||||
Revenue Adjustment Impact | ~+35 basis points | |||||||||||||||||||
Illustrative Foreign Currency (FX) Impact | (~25) basis points | |||||||||||||||||||
FY 2025 Revenue Growth (adjusted)(FXN) | + | |||||||||||||||||||
FY 2025 Inorganic Impact to Revenue Growth | ~+475 basis points | |||||||||||||||||||
FY 2025 Organic Revenue Growth(FXN) | + | |||||||||||||||||||
Total FY 2025 Revenues |
Notes |
- Revenue Adjustment Impact reflects the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. |
- Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. |
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2025 OUTLOOK RECONCILIATION CONTINUED
| ||||||||||||||||||||
Full Year FY 2025 Outlook | ||||||||||||||||||||
Full Year FY 2024 from Continuing Operations | Total Company | |||||||||||||||||||
Reported Diluted Earnings per Share | $ | 5.93 | ||||||||||||||||||
Purchase accounting adjustments ( | 5.16 | |||||||||||||||||||
Integration costs ( | 0.08 | |||||||||||||||||||
Restructuring costs ( | 1.33 | |||||||||||||||||||
Transaction Costs ( | 0.17 | |||||||||||||||||||
Financing Costs ( | (0.03) | |||||||||||||||||||
Separation-related items ( | 0.05 | |||||||||||||||||||
European regulatory initiative-related costs ( | 0.36 | |||||||||||||||||||
Product, litigation, and other items ( | 1.09 | |||||||||||||||||||
Tax impact of specified items and other tax related (( | (1.00) | |||||||||||||||||||
Adjusted Diluted Earnings per Share | $ | 13.14 | ||||||||||||||||||
Reported % Change | + |
(1) | Includes amortization and other adjustments related to the purchase accounting for acquisitions. |
(2) | Represents costs associated with integration and restructuring activities. |
(3) | Represents transaction costs and financing impacts associated with the acquisition of Edwards Lifesciences' Critical Care Product Group. The transaction costs are recorded in Integration, restructuring and transaction expense and the financing impacts are recorded in Interest income and Interest expense. |
(4) | Represents costs recorded to Other operating expense (income), net incurred in connection with the separation of BD's former Diabetes Care business. |
(5) | Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs. |
(6) | Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2024 reflects the recognition of |
View original content:https://www.prnewswire.com/news-releases/bd-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-302298182.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What was BD's (BDX) Q4 2024 revenue?
What is BD's (BDX) FY2025 organic growth guidance?
How much did BD's (BDX) Free Cash Flow grow in FY2024?